MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MannKind will present nine posters and late-breaking comparative data on Afrezza at the ADA 2026 Scientific Sessions in New Orleans, June 5-8. The data covers pediatric efficacy, treatment satisfaction, use with automated insulin delivery systems, and gestational diabetes, supporting the pending pediatric indication.
Key figures
- Drug Name
- Afrezza
- Pdufa date
- May 29, 2026
- Ada session dates
- June 5-8, 2026
- Number of posters
- 9
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.